Physician's Weekly
JUNE 17, 2025
TUESDAY, June 17, 2025 (HealthDay News) — Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder (SUD), according to a study published online June 11 in The American Journal of Psychiatry. Vinod Rao, M.D.,
FDA Law
JANUARY 5, 2023
Claud — As we turn into the New Year, we offer a few items of interest in digital and telehealth regulation, enforcement, and compliance that may provide some helpful guideposts for stakeholders. By John W.M. Remarks at the November AFDO/RAPS Combination Products Summit highlight the complexities of connected combination products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
JUNE 21, 2023
telemedicine and telehealth solutions (e.g., What processes and medical procedures, including diagnostics, do you believe would be ideal for transitioning from a hospital and/or healthcare setting to non-clinical care settings, for example, home use or school/work use? and remote or wearable patient monitoring devices (e.g.,
GeriPal
MARCH 28, 2024
Kate: So it was an embedded alert in the electronic health record and they just clicked those two answers very quickly. Kate: It was done in 10 hospitals, 17 ICUs in Atrium Health down in North Carolina. Also the same hospital system? Eric: And how did you do that? That’s when they got enrolled. Eric: Okay. Kate: 3,500.
GeriPal
JULY 20, 2023
This DEA is taking 6-months to consider how to move forward vis a vis restrictions and requirements for telehealth in a post-pandemic world. So we’re going to be talking about telemedicine, telehealth for people with serious illness. AlexSmithMD Transcript Eric: Welcome to the GeriPal podcast. This is Eric Widera. Eric: Yeah.
Expert insights. Personalized for you.
52 
Let's personalize your content